Empagliflozin (Standard)
Based on 1 Customer Validation
Empagliflozin (Standard) is the analytical standard of Empagliflozin. This product is intended for research and analytical applications. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.94%
- CAS No.: 864070-44-0
- Formule: C23H27ClO7
- Masse moléculaire:450.91
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Pureté et documentation
-
Help & FAQs
-
HY-N0142
PhloretinAnti-inflammatory Agent -
HY-N0143
PhlorizinSGLT Inhibitor -
HY-15409
EmpagliflozinSGLT2 Inhibitor -
HY-10450
DapagliflozinSGLT2 Inhibitor -
HY-10451
CanagliflozinSGLT2 Inhibitor -
HY-15516
SotagliflozinSGLT Inhibitor -
HY-10450R
Dapagliflozin (Standard)SGLT2 Inhibitor -
HY-15461
ErtugliflozinSGLT2 Inhibitor -
HY-14894
IpragliflozinSGLT Inhibitor -
HY-15461R
Ertugliflozin (Standard)SGLT2 Inhibitor -
HY-17638
MizagliflozinSGLT1 Inhibitor -
HY-I0383
Canagliflozin hemihydrateSGLT Inhibitor
Product Information
Information
Application
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 864070-44-0
-
Appearance Solid
-
Masse moléculaire 450.91
-
Formule C23H27ClO7
-
Color White to off-white
-
SMILES
ClC(C=CC([C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)=C2)=C2CC(C=C3)=CC=C3O[C@H]4CCOC4
-
Synonyms
BI 10773 (Standard)
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Grempler R, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012 Jan;14(1):83-90. [Content Brief]
[2]. Cheng ST, et al. The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes. PLoS One. 2016 Jan 25;11(1):e0147391. [Content Brief]
[4]. Sakaeda T, et al. Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors. Int J Med Sci. 2018 Jun 13;15(9):937-943. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Empagliflozin (Standard) Related Classifications
HY-15409R Related Classifications
Powered by Bioz